<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00466791</url>
  </required_header>
  <id_info>
    <org_study_id>SPD485-201</org_study_id>
    <nct_id>NCT00466791</nct_id>
  </id_info>
  <brief_title>Classroom Study to Assess Efficacy and Safety of MTS in Pediatric Patients Aged 6-12 With ADHD</brief_title>
  <official_title>A Phase II, Randomized, Double-blind, Multi-center, Placebo-controlled, Dose Optimization, Analog Classroom, Crossover Study Designed to Assess the Time Course of Treatment Effect, Tolerability and Safety of Methylphenidate Transdermal System (MTS) in Pediatric Patients Aged 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Noven Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Noven Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the behavioral effects of MTS in children aged 6-12 with ADHD
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluate the behavioral effects measured by the SKAMP deportment scale of MTS compared to
      placebo in children aged 6-12 with ADHD
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <completion_date type="Actual">May 2005</completion_date>
  <primary_completion_date type="Actual">May 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Score on SKAMP rating scale at 2,3,4.5,6,7.5,9,10.5 and 12 hours post application of MTS</measure>
    <time_frame>2,3,4.5,6,7.5,9,10.5 and 12 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PERMP scores</measure>
    <time_frame>pre-dose, 2.0, 3.0, 4.5, 6.0, 7.5, 9.0, 10.5 and 12.0 hours post application</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinician-rated ADHD-RS-IV score</measure>
    <time_frame>2,3,4.5,6,7.5,9,10.5 and 12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGI-I score</measure>
    <time_frame>Weeks 1-9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PGA</measure>
    <time_frame>Weeks 1-9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CPRS-R score</measure>
    <time_frame>Weeks 1-9</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">93</enrollment>
  <condition>Attention Deficit Disorder With Hyperactivity</condition>
  <arm_group>
    <arm_group_label>Methylphenidate Transdermal System</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Transdermal patch, 27.5mg, 41.3mg, 55mg, and 82.5mg, daily for 11 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Transdermal patch, 0mg, daily for 11 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylphenidate Transdermal System</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Methylphenidate Transdermal System</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>ADHD Patch</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary diagnosis ADHD

          -  Total score of greater than or equal to 26 on ADHD-RS-IV

          -  IQ of greater than or equal to 80

          -  Blood pressure measurements within 95th percentile for age, gender, height at
             screening and baseline

        Exclusion Criteria:

          -  Current controlled (requiring a restricted medication) or uncontrolled, comorbid
             psychiatric diagnosis (except ODD)

          -  Known nonresponder to psychostimulant treatment

          -  BMI for age greater than 90th percentile

          -  History of seizures during last 2 years

          -  Conduct Disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UCI Child Development Center</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?CFID=20377655&amp;CFTOKEN=caaa9085d296aa43-A8C6AE4E-1143-D1C5-FB7BD1C853149DF7</url>
    <description>FDA-approved labelling information, US only</description>
  </link>
  <link>
    <url>http://www.fda.gov/opacom/7alerts.html</url>
    <description>FDA Recall information</description>
  </link>
  <results_reference>
    <citation>McGough JJ, Wigal SB, Abikoff H, Turnbow JM, Posner K, Moon E. A randomized, double-blind, placebo-controlled, laboratory classroom assessment of methylphenidate transdermal system in children with ADHD. J Atten Disord. 2006 Feb;9(3):476-85.</citation>
    <PMID>16481664</PMID>
  </results_reference>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2007</study_first_submitted>
  <study_first_submitted_qc>April 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2007</study_first_posted>
  <last_update_submitted>June 23, 2015</last_update_submitted>
  <last_update_submitted_qc>June 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
    <mesh_term>Hyperkinesis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylphenidate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

